Clinical trial
Treatment for Subjects With Non-Hodgkin's Lymphoma
NCT00117897 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00117897 |
|---|---|
| Title | Treatment for Subjects With Non-Hodgkin's Lymphoma |
| Official title | An Open-Label, Randomized, Parallel, Phase II Study of CHOP Chemotherapy and Rituximab Administered Every 14 Days, With Pegfilgrastim or Filgrastim Support, for the Treatment of Subjects With Non-Hodgkin's Lymphoma |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | pegfilgrastim, Filgrastim |
| Start date | Jul 1, 2002 |
| Completion | Feb 1, 2004 |
| First posted | Jul 11, 2005 |
| Last update posted | Jul 20, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: